drug_type
RELEVANT_DRUG
intervention_type
monoclonal antibody
drug_description
A monoclonal antibody that targets the urokinase plasminogen activator receptor (uPAR); in this trial it serves as the targeting moiety for radioimmunotherapy when chelated and labeled with lutetium-177.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Monoclonal
drug_category
RADIOIMMUNOCONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
MNPR-101 is a uPAR-targeting monoclonal antibody chelated with PCTA and labeled with lutetium-177. Binding to uPAR on tumor and tumor-associated stromal cells localizes beta-emitting 177Lu to the lesion, delivering ionizing radiation that causes DNA double-strand breaks and cell death, with a crossfire effect to neighboring cells.
drug_name
MNPR-101
nct_id_drug_ref
NCT06617169